PDF(Pubmed)
Abstract：
BACKGROUND: This study\'s purposes were to evaluate the impact of biological therapies on outcomes in patients with severe asthma (SA) and chronic rhinosinusitis (CRS) and to compare these effects among those with NP (CRSwNP) versus those without NP (CRSsNP) in the \"real-world\" setting in Saudi Arabian patients.
METHODS: From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP.
RESULTS: Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (p < 0.001), respectively. However, after 12 months of dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%.
CONCLUSIONS: Patients with CRS experienced significant improvements in clinical, FEV1, and laboratory outcomes after dupilumab therapy. However, these improvements were not maintained when comparing CRSwNP with CRSsNP. There were no significant differences between those with and without NP regarding ACT and OCs use or laboratory (eosinophilic count, serum IgE level) parameters. Further prospective multicenter studies are warranted.
METHODS: From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP.
RESULTS: Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (p < 0.001), respectively. However, after 12 months of dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%.
CONCLUSIONS: Patients with CRS experienced significant improvements in clinical, FEV1, and laboratory outcomes after dupilumab therapy. However, these improvements were not maintained when comparing CRSwNP with CRSsNP. There were no significant differences between those with and without NP regarding ACT and OCs use or laboratory (eosinophilic count, serum IgE level) parameters. Further prospective multicenter studies are warranted.
摘要：
背景：本研究的目的是评估生物治疗对严重哮喘（SA）和慢性鼻-鼻窦炎（CRS）患者预后的影响，并比较沙特阿拉伯患者中NP（CRSwNP）和无NP（CRSsNP）患者的这些影响。
方法：从2022年3月至9月，在南部地区武装部队医院（AFHSR）和哈立德国王大学医院的严重哮喘诊所进行了一项回顾性观察性队列研究。Abha,沙特阿拉伯,描述dupilumab治疗的效果。对结果进行了评估，包括临床结果，FEV1，以及dupilumab之前和之后一年的实验室检查结果。比较CRSwNP和CRSsNP的治疗后效果。
结果：纳入了50名受试者，平均年龄46.56岁.有27名（54％）女性和23名（46％）男性。临床参数的显着改善（哮喘加重和住院的频率，使用OCs，嗅觉缺失,SNOTT-22和ACT)，使用dupilumab后6个月和12个月观察到FEV1和实验室（血清IgE和嗜酸性粒细胞计数）（p<0.001），分别。然而,dupilumab治疗12个月后，有和没有NP的人在临床上没有显着差异(嗅觉缺失，ACT,和OC使用)，实验室(嗜酸性粒细胞计数，血清IgE水平）参数，和FEV1%。
结论：CRS患者在临床上有显著改善，FEV1和dupilumab治疗后的实验室结果。然而,当比较CRSwNP与CRSsNP时,这些改善未得到维持.有和没有NP的人在ACT和OCs使用或实验室方面没有显著差异(嗜酸性粒细胞计数，血清IgE水平）参数。进一步的前瞻性多中心研究是必要的。
方法：从2022年3月至9月，在南部地区武装部队医院（AFHSR）和哈立德国王大学医院的严重哮喘诊所进行了一项回顾性观察性队列研究。Abha,沙特阿拉伯,描述dupilumab治疗的效果。对结果进行了评估，包括临床结果，FEV1，以及dupilumab之前和之后一年的实验室检查结果。比较CRSwNP和CRSsNP的治疗后效果。
结果：纳入了50名受试者，平均年龄46.56岁.有27名（54％）女性和23名（46％）男性。临床参数的显着改善（哮喘加重和住院的频率，使用OCs，嗅觉缺失,SNOTT-22和ACT)，使用dupilumab后6个月和12个月观察到FEV1和实验室（血清IgE和嗜酸性粒细胞计数）（p<0.001），分别。然而,dupilumab治疗12个月后，有和没有NP的人在临床上没有显着差异(嗅觉缺失，ACT,和OC使用)，实验室(嗜酸性粒细胞计数，血清IgE水平）参数，和FEV1%。
结论：CRS患者在临床上有显著改善，FEV1和dupilumab治疗后的实验室结果。然而,当比较CRSwNP与CRSsNP时,这些改善未得到维持.有和没有NP的人在ACT和OCs使用或实验室方面没有显著差异(嗜酸性粒细胞计数，血清IgE水平）参数。进一步的前瞻性多中心研究是必要的。
